Compare Apple Inc (AAPL) vs Moderna, Inc. (MRNA) Price & Performance

Apple (AAPL) trades at $314.03, up 0.44% today, with a bullish technical signal from moving averages and a consensus analyst price target of $329.62. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.01 surpassing the $1.95 estimate. Revenue grew to $416.16B in 2025, and net income reached $112.01B. The company maintains strong profitability with a 47.86% gross margin and 27.15% net margin, though valuation ratios like P/E of 37.61 are elevated. A dividend of $0.27 is scheduled for payment on May 14, 2026.

The outlook for AAPL remains positive driven by earnings beats and AI opportunities, but risks include high valuation, competitive pressures, and potential regulatory scrutiny. Institutional sentiment is bullish with 62.73% buy ratings, though technical indicators show mixed signals with RSI suggesting mild overbought conditions near-term.

Moderna (MRNA) trades at $79.77, up 0.01% on the day, with a bullish technical signal from moving averages and positive momentum from recent pipeline news. The stock has seen significant gains, driven by FDA progress on its mRNA flu vaccine and expansion into oncology and rare diseases. However, fundamentals show persistent losses, with a net income margin of -144.92% in 2025 and declining revenue from pandemic peaks, though quarterly EPS has beaten expectations recently.

The outlook is mixed: strong technical momentum and pipeline diversification offer upside, but high valuation ratios and sustained unprofitability pose risks. Analyst consensus is cautious with a $48.83 price target, suggesting 39% downside, indicating Wall Street sees limited near-term fundamental support despite recent bullish sentiment.